Na-enyocha...
Atụgharịrị ya na-akpaghị aka. Maka ọnụọgụ ọgwụ na ịdọ aka ná ntị: lee nke mbụ n'asụsụ Bekee. Gụọ n'asụsụ Bekee
Home / Ọgwụ A–Z / Montelukast

Montelukast

Montelukast sodium tablets are a leukotriene receptor antagonist indicated for: Prophylaxis and chronic treatment of asthma in patients 15 years of ag.

Prescription medicine Oral Safety alerts on record

How to use Montelukast

What the official label says. If a doctor prescribed it, follow the prescription. Your pack's leaflet comes first if it is different.

Serious warning: SERIOUS NEUROPSYCHIATRIC EVENTS WARNING: SERIOUS NEUROPSYCHIATRIC EVENTS Serious neuropsychiatric (NP) events have been reported with the use of montelukast sodium tablets. The types of events reported were highly variable, and included, but were not limited to, agitation, aggression, depression, sleep disturbances, suicidal thoughts and behavior (including suicide). …
Who it is for

Montelukast sodium tablets are a leukotriene receptor antagonist indicated for: Prophylaxis and chronic treatment of asthma in patients 15 years of age and older ( 1.1 ). Acute prevention of exercise-induced bronchoconstriction (EIB) in patients 15 years of age and older ( 1.2 ). Relief of symptoms of allergic rhinitis (AR): seasonal allergic rhinitis (SAR) in patients 15 years of age and older, and perennial allergic rhinitis (PAR) in patients 15 years of age and older. Reserve use for patients who have an inadequate response or intolerance to alternative therapies ( 1.3 ). Limitations of Use: Not indicated to treat an acute asthma attack ( 5.2 ). …

How to take it and how often
  • Administration (by indications): Asthma: Once daily in the evening for patients 15 years of age and older
  • Acute prevention of EIB: One tablet at least 2 hours before exercise for patients 15 years of age and older
  • Seasonal allergic rhinitis: Once daily for patients 15 years and older
  • Perennial allergic rhinitis: Once daily for patients 15 years and older
  • Dosage (by age): 15 years and older: one 10-mg tablet
  • Patients with both asthma and allergic rhinitis should take only one dose daily in the evening
  • Asthma For asthma, administer montelukast sodium orally once daily in the evening, with or without food
  • There have been no clinical trials in patients with asthma to evaluate the relative efficacy of morning versus evening dosing
  • The following doses are recommended: Table 1: Recommended Dosage in Asthma Age Dose Adult and adolescent patients 15 years of age and older one 10 mg tablet Patients who miss a dose should take the next dose at their regular time and should not take 2 doses at the same time
  • Exercise-Induced Bronchoconstriction (EIB)
  • For prevention of EIB, administer a single dose of montelukast sodium orally at least 2 hours, before exercise
  • The following doses are recommended: Table 2: Recommended Dosage in Exercise-Induced Bronchoconstriction (EIB) Age Dose Adult and adolescent patients 15 years of age and older one 10 mg tablet An additional dose of montelukast sodium should not be taken within 24 hours of a previous dose. …
Strengths it comes in

Montelukast sodium tablets, USP 10 mg, are beige colour, rounded square shaped, biconvex, film-coated tablet debossed with 'CL 26' on one side and plain on the other side. • Tablets: 10 mg ( 3 )

Children
  • The safety and effectiveness
  • In pediatric patients below the age of 12 months with asthma, 6 months with perennial allergic rhinitis, and 6 years with exercise-induced bronchoconstriction have not been established
Older adults

Of the total number of subjects in clinical studies of montelukast, 3.5% were 65 years of age and over, and 0.4% were 75 years of age and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. …

While you are taking it
  • For the tablets, advise the patient and/or caregiver to read the FDA-approved patient labeling (Medication Guide)
  • Advise patients about the potential risk for serious neuropsychiatric symptoms and behavioral changes with montelukast sodium use [see Warnings and Precautions ]
  • Discuss the benefits and risks of montelukast sodium with patients when prescribing or continuing treatment with montelukast sodium [see Warnings and Precautions ]
  • Advise patients to monitor for changes in behavior or neuropsychiatric symptoms in patients taking montelukast sodium [see Warnings and Precautions ]. …
Talk to a doctor first if
  • Montelukast sodium is contraindicated in patients with hypersensitivity to any of its components
  • Hypersensitivity to any component of montelukast sodium
Medicines it may not mix with

No dose adjustment is needed when montelukast sodium is co-administered with theophylline, prednisone, prednisolone, oral contraceptives, fexofenadine, digoxin, warfarin, gemfibrozil, itraconazole, thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, decongestants, and Cytochrome P450 (CYP) enzyme inducers [see Clinical Pharmacology ( 12.3 )].

Warnings

Do not prescribe montelukast sodium to treat an acute asthma attack ( 5.2 ). Advise patients to have appropriate rescue medication available ( 5.2 ). Inhaled corticosteroid may be reduced gradually. Do not abruptly substitute montelukast sodium for inhaled or oral corticosteroids ( 5.3 ). Patients with known aspirin sensitivity should continue to avoid aspirin or non-steroidal anti-inflammatory agents while taking montelukast sodium ( 5.4 ). Systemic eosinophilia, sometimes presenting with clinical features of vasculitis consistent with Churg-Strauss syndrome, has been reported. These events have been sometimes associated with the reduction of oral corticosteroid therapy ( 5.5 and 6.2 ). …

Possible side effects

The following clinically significant adverse reactions are described elsewhere in the labeling: Neuropsychiatric Events [see Warnings and Precautions ( 5.1 )] Most common adverse reactions (incidence ≥ 5% and greater than placebo listed in descending order of frequency): upper respiratory infection, fever, headache, pharyngitis, cough, abdominal pain, diarrhea, otitis media, influenza, rhinorrhea, sinusitis, otitis ( 6.1 ). To report SUSPECTED ADVERSE REACTIONS, contact Macleods Pharma USA, Inc., at 1-888-943-3210 or 1-855-926-3384 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . …

Pregnancy and breastfeeding

8.1 Pregnancy Risk Summary Available data from published prospective and retrospective cohort studies over decades with montelukast use in pregnant women have not established a drug-associated risk of major birth defects [see Data]. …

If you take too much

No specific information is available on the treatment of overdosage with montelukast sodium. In the event of overdose, it is reasonable to employ the usual supportive measures; e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring, and institute supportive therapy, if required. It is not known whether montelukast is removed by peritoneal dialysis or hemodialysis.

If you miss a dose

Take it when you remember, unless it is nearly time for the next dose. Then skip the missed one. Never take two doses at once to make up for it. Check your leaflet, as some medicines are different.

From the official U.S. FDA label for this active ingredient. Your pack may have a different strength, so always read its leaflet. If a doctor prescribed it, follow the prescription. Ask a pharmacist if you are unsure. Label dated 2025-05-30.

Brands around the world

Products with Montelukast as the active ingredient. Names differ between countries.

Registered products

United States (FDA)

Montelukast SodiumMONTELUKAST SODIUM 10 mg/1 · Tablet, Film Coated · ORGANON PHARMA (UK) LIMITED
NDC 60312-0117Label
Montelukast SodiumMONTELUKAST SODIUM 10 mg/1 · Tablet, Coated · Dr. Reddy's Laboratories Limited
NDC 55111-725Label
Montelukast SodiumMONTELUKAST SODIUM 5 mg/1 · Tablet, Chewable · ORGANON PHARMA (UK) LIMITED
NDC 60312-0275Label
Montelukast SodiumMONTELUKAST SODIUM 10 mg/1 · Tablet, Film Coated · Aurobindo Pharma Limited
NDC 65862-574Label
Montelukast SodiumMONTELUKAST SODIUM 10 mg/1 · Tablet, Film Coated · Rising Pharma Holdings, Inc.
NDC 57237-255Label

Nigeria (NAFDAC)

NAFDACMontelukast Sodium USP 4 mg Tablet C4-1795NAFDACMontelukast Sodium USP 10 mg Tablet C4-1796NAFDACMontelukast Sodium USP 10 mg & Levocetrizine Hydrochloride 5 mg Tablet C4-1797NAFDACAsthator 5 B4-1262NAFDACAsthator 10 B4-1308NAFDACLevomonte Syrup A11-100190NAFDACMontral Tablets B4-6888NAFDACZobix 15 Tablet A4-101283NAFDACGlemont L Tablets B4-2678NAFDACMontiget 4 mg Tablet A4-0296NAFDACMontiget 10 mg Tablet A4-8766NAFDACMontiget Chewable Tablet A4-8765

Other countries: check your pack's registration number and we point you to your regulator.

Safety alerts and recalls

Montelukast Sodium Tablets, USP 10 mg, Rx Only, 1000 count bottle, Distributed by: Dr. Reddy's Laboratories., Princeton, NJ 08540, Made in India, NDC# 55111-725-10.U.S. FDA Class II
13 Oct 2023 · Dr. Reddy's Laboratories, Inc. · TerminatedPresence of Foreign Tablet(s)/Capsule(s): A foreign tablet was found in a bottle of Montelukast Sodium Tablets, USP 10mg, identified as metoprolol 25 mg.
Montelukast Sodium USP, 10 mg, 30 count-bottles, Rx only, Intas Pharm, Limited Ahmedabad 380 054 India Pkg By: PD-Rx Pharmaceuticals Incorporated Oklahoma City, OK 73127, NDC 43063U.S. FDA Class II
6 Apr 2023 · PD-Rx Pharmaceuticals, Inc. · TerminatedCGMP deviations.
Montelukast Sodium Oral Granules USP, 4 mg, packaged in a carton containing 30 packets, Rx only, Distributed By: Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054, Carton NDC 00U.S. FDA Class III
27 Mar 2023 · Teva Pharmaceuticals USA Inc · TerminatedFailed Impurities/Degradation Specifications: failed impurities for Sulphoxide and Impurity A.
Montelukast Sodium Tablets, USP, 10 mg, packaged in: a) 30-count bottle (NDC 68788-9438-3); b) 60-count bottle (NDC 68788-9438-6); c) 90-count bottle (NDC 68788-9438-9), Rx only, MU.S. FDA Class II
23 Mar 2023 · Preferred Pharmaceuticals, Inc. · OngoingcGMP Deviations for the manufacturing Firm (Accord Healthcare) after their inspection.

A recall usually affects certain batches only. Compare the lot number on your pack.

Check your pack of Montelukast

Or take photos of the pack
3 free checks left today Official sources: U.S. FDA · EMA (EU) · NAFDAC · WHO alerts

Questions about Montelukast

What is Montelukast used for?

Montelukast sodium tablets are a leukotriene receptor antagonist indicated for: Prophylaxis and chronic treatment of asthma in patients 15 years of age and older ( 1.1 ). Acute prevention of exercise-induced bronchoconstriction (EIB) in patients 15 years of age and older ( 1.2 ). Relief of symptoms of allergic rhinitis (AR): seasonal allergic rhinitis (SAR) in patients 15 years of age and older, and perennial allergi (From the official U.S. FDA label.)

How do I take Montelukast?

Follow your prescription or the leaflet in your pack. The official label says: Administration (by indications): Asthma: Once daily in the evening for patients 15 years of age and older ( 2.1 ). Acute prevention of EIB: One tablet at least 2 hours before exercise for patients 15 years of age and older ( 2.2 ). Seasonal allergic rhinitis: Once daily for patients 15 years and older ( 2.3 ). Perennial allergic rhinitis: Once daily for patients 15 years and ol…

Do I need a prescription for Montelukast?

Usually yes. Montelukast is a prescription medicine in most countries. Rules differ by country.

What brands contain Montelukast?

Montelukast is sold under names such as Singulair, Montelukast. Brand names differ between countries.

How can I check that my Montelukast is genuine?

Scan the registration number on your pack with PillVera (NAFDAC number in Nigeria, NDC in the United States, DIN in Canada), check the expiry date and buy only from licensed pharmacies.